San Diego, CA -- (SBWIRE) -- 03/20/2018 -- The Shareholders Foundation announces that an investor, who purchased shares of Akorn, Inc. (NASDAQ:AKRX), filed a lawsuit over alleged Securities Laws violations by Akorn, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Akorn, Inc. (NASDAQ:AKRX) should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On April 24, 2017, Fresenius Kabi has agreed to acquire Akorn (NASDAQ: AKRX) for approximately $4.3 billion, or $34.00 a share, plus the assumption of approximately $450 million of debt1. The transaction is expected to close by early 2018 and to be accretive in 2018 to Fresenius Group net income and EPS, excluding integration costs.

On February 26, 2018, Fresenius SE & Co. KGaA announced it is "conducting an independent investigation, using external experts, into alleged breaches of FDA [Food and Drug Administration] data integrity requirements relating to product development at Akorn, Inc." Fresenius also stated the "consummation of the transaction may be affected if the closing conditions under the merger agreement are not met."

Shares of Akorn, Inc. (NASDAQ:AKRX) declined from $32.26 per share on February 15, 2018 to as low as $16.79 per share on February 28, 2018.

According to the complaint the plaintiff alleges on behalf of purchasers of Akorn, Inc. (NASDAQ:AKRX) common shares between March 1, 2017 and February 26, 2018, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between March 1, 2017 and February 26, 2018, the defendants made materially false and/or misleading statements and/or failed to disclose that: Akorn's failure to comply with FDA data integrity requirements would jeopardize Fresenius's acquisition of Akorn, that Akorn lacked effective internal controls over financial reporting, and that as a result, Akorn's financial statements were materially false and misleading at all relevant times

Those who purchased shares of Akorn, Inc. (NASDAQ:AKRX) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com